Sensus Healthcare (SRTS) Stock Overview
Operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SRTS Community Fair Values
Create NarrativeSee what 63 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
NA
Community Contributor
SRTS Market Outlook
Sensus Healthcare, Inc. (NASDAQ: SRTS) specializes in non-invasive treatments for skin conditions, notably through its Superficial Radiation Therapy (SRT) technology.
View narrativeUS$13.42
FV
70.3% undervalued intrinsic discount20.39%
Revenue growth p.a.
1.6k
users have viewed this narrative6users have liked this narrative
0users have commented on this narrative
44users have followed this narrative
Sensus Healthcare, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.98 |
| 52 Week High | US$5.92 |
| 52 Week Low | US$3.03 |
| Beta | 1.28 |
| 1 Month Change | -3.16% |
| 3 Month Change | -22.11% |
| 1 Year Change | -8.08% |
| 3 Year Change | 40.14% |
| 5 Year Change | 17.06% |
| Change since IPO | -31.97% |
Recent News & Updates
SRTS: 2026 Reimbursement Codes And New Platform Rollout Will Drive Upside
Narrative Update Overview Analysts have trimmed their average price target on Sensus Healthcare from $8.00 to $7.50, reflecting mixed views that balance expectations for stronger SRT platform revenue supported by new 2026 reimbursement codes, alongside the impact of recent quarterly results that fell short due to no sales from a key customer. Analyst Commentary Bullish analysts remain constructive on Sensus Healthcare, pointing to the company’s SRT platform and upcoming reimbursement changes as key elements that could support long term growth.SRTS: 2026 Reimbursement Shift Will Support Future Skin Therapy Adoption
Analysts have updated the price target range for Sensus Healthcare. One analyst raised the target to $7.50, citing expectations for SRT platform revenue supported by new 2026 reimbursement codes.SRTS: Reimbursement Shift In 2026 Will Drive Future Upside Potential
Narrative Update: Sensus Healthcare (SRTS) The blended analyst price target for Sensus Healthcare has shifted from $8 to $7.50. Analysts are balancing expectations for very strong SRT platform revenue in 2026, tied to new reimbursement codes, with the impact of Q4 results that missed forecasts due to no sales from the company’s largest customer.
SRTS: Future Upside Will Depend On 2026 Reimbursement Code Changes
Analysts have nudged their fair value estimate for Sensus Healthcare slightly higher to $6.88, reflecting mixed recent research in which one firm trimmed its price target to $6 after weak Q4 results, while another initiated coverage with a more upbeat $7.50 target tied to expectations for the SRT platform and 2026 reimbursement changes. Analyst Commentary Bullish Takeaways Bullish analysts point to the SRT-100/Vision platform as the core driver of the current fair value view, given its focus on treating both oncological and non-oncological skin conditions, which supports their more constructive stance on long term growth potential.Recent updates
SRTS: 2026 Reimbursement Codes And New Platform Rollout Will Drive Upside
Narrative Update Overview Analysts have trimmed their average price target on Sensus Healthcare from $8.00 to $7.50, reflecting mixed views that balance expectations for stronger SRT platform revenue supported by new 2026 reimbursement codes, alongside the impact of recent quarterly results that fell short due to no sales from a key customer. Analyst Commentary Bullish analysts remain constructive on Sensus Healthcare, pointing to the company’s SRT platform and upcoming reimbursement changes as key elements that could support long term growth.SRTS: 2026 Reimbursement Shift Will Support Future Skin Therapy Adoption
Analysts have updated the price target range for Sensus Healthcare. One analyst raised the target to $7.50, citing expectations for SRT platform revenue supported by new 2026 reimbursement codes.SRTS: Reimbursement Shift In 2026 Will Drive Future Upside Potential
Narrative Update: Sensus Healthcare (SRTS) The blended analyst price target for Sensus Healthcare has shifted from $8 to $7.50. Analysts are balancing expectations for very strong SRT platform revenue in 2026, tied to new reimbursement codes, with the impact of Q4 results that missed forecasts due to no sales from the company’s largest customer.SRTS: Future Upside Will Depend On 2026 Reimbursement Code Changes
Analysts have nudged their fair value estimate for Sensus Healthcare slightly higher to $6.88, reflecting mixed recent research in which one firm trimmed its price target to $6 after weak Q4 results, while another initiated coverage with a more upbeat $7.50 target tied to expectations for the SRT platform and 2026 reimbursement changes. Analyst Commentary Bullish Takeaways Bullish analysts point to the SRT-100/Vision platform as the core driver of the current fair value view, given its focus on treating both oncological and non-oncological skin conditions, which supports their more constructive stance on long term growth potential.SRTS: Future Upside Will Hinge On Reducing Largest Customer Concentration Risk
Narrative Update on Sensus Healthcare Analysts have trimmed their price target on Sensus Healthcare to $6 from $8, pointing to Q4 results that came in well below their expectations after the company reported no sales from its largest customer. Analyst Commentary Analysts are adjusting their views on Sensus Healthcare after the latest Q4 report, with the lower price target reflecting both execution concerns and how the market may now be valuing the shares.Sensus Healthcare, Inc. (NASDAQ:SRTS) Just Reported And Analysts Have Been Cutting Their Estimates
Feb 15
SRTS: Auditor Transition And Margin Outlook Will Support Future Upside
Analysts have reduced their price target on Sensus Healthcare to US$20.65 from US$21.29, reflecting updated assumptions that include slightly higher projected revenue growth, a modestly stronger profit margin profile, and a marginally lower future P/E multiple. What's in the News Auditor change: Sensus Healthcare's Audit Committee dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP and approved Carr, Riggs & Ingram, LLC as the new independent registered public accounting firm following CRI's acquisition of certain BPB capital markets assets, effective January 1, 2026 (Key Developments).SRTS: Slightly Improved Outlook And Auditor Transition Will Support Future Upside
Analysts have raised their price target on Sensus Healthcare by a small amount, citing slightly higher assumptions for revenue growth and profit margins, along with a modestly lower discount rate and a marginally reduced future P/E multiple. What's in the News The Audit Committee of Sensus Healthcare's Board of Directors dismissed Berkowitz Pollack Brant Advisors + CPAs, LLP as the independent registered public accounting firm and approved Carr, Riggs & Ingram, LLC as the new auditor, following CRI's acquisition of certain capital markets assets from BPB effective January 1, 2026 (company filing).Sensus Healthcare, Inc.'s (NASDAQ:SRTS) Share Price Boosted 38% But Its Business Prospects Need A Lift Too
Jan 14SRTS: Keloid Treatment Breakthrough Will Support Stronger Prospects Despite Trimmed Outlook
Narrative Update on Sensus Healthcare Analysts have modestly raised their price target on Sensus Healthcare, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E. Together, these adjustments support a higher fair value estimate now framed at US$8.00.SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have modestly lifted their price target on Sensus Healthcare to reflect slightly faster expected revenue growth and improving profit margins, even as they temper future valuation multiples. Valuation Changes Discount Rate has risen slightly from 7.69% to 7.70%, reflecting a marginally higher required return.SRTS: Keloid Treatment Breakthrough Will Drive Stronger Prospects Despite Trimmed Outlook
Analysts have trimmed their price target on Sensus Healthcare to approximately 8 dollars from about 10 dollars, citing softer expected revenue growth, lower projected profit margins, and a higher assumed future price to earnings multiple that together point to a more conservative valuation outlook. What's in the News Peer reviewed data from a single center retrospective study in Dermatologic Therapy show that Sensus Healthcare's superficial radiotherapy technology combined with punch excision significantly improved keloid outcomes over one year, including reductions in pain, itching, thickness and irregularity of scars, with no severe adverse reactions reported (study in Dermatologic Therapy).Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Rockets 26% But Many Are Still Ignoring The Company
Nov 19Insufficient Growth At Sensus Healthcare, Inc. (NASDAQ:SRTS) Hampers Share Price
Oct 04Increased CMS Reimbursement And International Expansion Will Unlock Demand
With no new analyst reasoning provided and both the discount rate and future P/E ratio remaining stable, the consensus fair value for Sensus Healthcare is unchanged at $8.00. What's in the News Sensus Healthcare's entire superficial radiation therapy (SRT) system portfolio received Medical Device Single Audit Program (MDSAP) certification.Returns On Capital Are Showing Encouraging Signs At Sensus Healthcare (NASDAQ:SRTS)
Jul 12Why Sensus Healthcare, Inc. (NASDAQ:SRTS) Could Be Worth Watching
May 06Investors Shouldn't Be Too Comfortable With Sensus Healthcare's (NASDAQ:SRTS) Earnings
Mar 13Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock's 27% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Feb 25Revenue Beat: Sensus Healthcare, Inc. Beat Analyst Estimates By 5.6%
Feb 08SRTS Market Outlook
Sensus Healthcare (NASDAQ: SRTS) operates in the Healthcare sector and is part of the Medical Devices industry. Specifically, it focuses on the development and commercialization of non-invasive SuperfWe Think Sensus Healthcare (NASDAQ:SRTS) Might Have The DNA Of A Multi-Bagger
Dec 18Results: Sensus Healthcare, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Nov 19Sensus Healthcare, Inc. (NASDAQ:SRTS) Doing What It Can To Lift Shares
Nov 12At US$6.10, Is It Time To Put Sensus Healthcare, Inc. (NASDAQ:SRTS) On Your Watch List?
Oct 03
Fair Deal Agreement And Global Expansion Set To Revolutionize Revenue And Margins
Strategic shift towards recurring revenue with the Fair Deal Agreement model indicates potential for significant revenue growth from 2025.Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up
May 12Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk
Apr 16Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 11There's Been No Shortage Of Growth Recently For Sensus Healthcare's (NASDAQ:SRTS) Returns On Capital
Oct 17Shareholder Returns
| SRTS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.0% | -4.2% | 0.8% |
| 1Y | -8.1% | -18.5% | 27.8% |
Return vs Industry: SRTS exceeded the US Medical Equipment industry which returned -18.5% over the past year.
Return vs Market: SRTS underperformed the US Market which returned 27.8% over the past year.
Price Volatility
| SRTS volatility | |
|---|---|
| SRTS Average Weekly Movement | 8.8% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SRTS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SRTS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 60 | Joe Sardano | sensushealthcare.com |
Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Sensus Healthcare, Inc. Fundamentals Summary
| SRTS fundamental statistics | |
|---|---|
| Market cap | US$65.52m |
| Earnings (TTM) | -US$7.72m |
| Revenue (TTM) | US$27.48m |
2.4x
P/S Ratio-8.5x
P/E RatioIs SRTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRTS income statement (TTM) | |
|---|---|
| Revenue | US$27.48m |
| Cost of Revenue | US$15.62m |
| Gross Profit | US$11.87m |
| Other Expenses | US$19.59m |
| Earnings | -US$7.72m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 43.18% |
| Net Profit Margin | -28.09% |
| Debt/Equity Ratio | 0% |
How did SRTS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 06:42 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sensus Healthcare, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Alexander Nowak | Craig-Hallum Capital Group LLC |